The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter.
The pharmaceutical stock is struggling, but its dividend can be highly valuable to income investors.
Zacks Investment Research on MSN
Pfizer stock rises almost 9% in 3 months: Time to buy, hold or exit?
Pfizer PFE stock has risen 8.6% in the past three months as investors have gained confidence in the company’s ability to ...
Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are ...
Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.
Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about ...
Pfizer's pipeline strength is evident, especially with berobenatide and Vyndamax, providing a bridge over the 2028 LOE trough ...
The Food and Drug Administration has approved the latest version of Pfizer and BioNTech's COVID-19 vaccine, the companies announced Thursday.
Pfizer (PFE) has drawn fresh attention after the FDA approved its 2026 to 2027 COMIRNATY XFG COVID-19 vaccine formula for ...
Patient investors who buy the stock may be rewarded over the long term.
The two companies had announced on Monday that NIL had inked an agreement with Pfizer Inc to acquire the trademarks for India ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results